Similarly, in lung cancer, radioresistance-related signatures also predict patient outcomes and immune status (31), identifying TOP2A, CDH3, ASPM, CENPF, SLC2A1, and PRC1 as potential detection biomarkers for early lung cancer (32). This evidence concerns the gene PRC1 and lung carcinoma.